About
Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-enabled design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications. Partnered with leading biopharmaceutical companies, AI Proteins continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.
Focus
Lease
Markets
FAQs
AI Proteins has financed 1 deal.
AI Proteins's most recent deal was on January 29, 2026.
Member since: January 2026
Deals
Transaction Type
Asset Type
State
Sort By
LEASED
Kimberly Sherman Stamler And Bruce A. Beal Lease 40,000 Square Feet To AI Proteins In Boston
660 Commonwealth Avenue, Boston, MA
MACRE
Jan 29, 2026